Scoop: No­var­tis’ re­treat on CAR-T in­cludes ax­ing most of its se­nior ex­ecs on the team

No­var­tis’ plan to pull back on CAR-T in­cludes purg­ing most of the se­nior ex­ecs in­volved in the project, sig­nal­ing the phar­ma gi­ant’s R&D re­treat is more ex­ten­sive than the com­pa­ny has want­ed to ad­mit so far.

End­points News, which broke the sto­ry on No­var­tis’ sur­pris­ing R&D move, ini­tial­ly ob­tained the top frag­ment of an in­ter­nal cor­po­rate memo au­thored by Us­man “Oz” Azam at No­var­tis spelling out that the com­pa­ny is dis­solv­ing its cell and gene ther­a­py unit re­spon­si­ble for its pi­o­neer­ing work on CAR-T. Now we have the rest of it, and it in­cludes this on the team ex­ecs:

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters